85 search results for: pediatric

Dupilumab Reduces Total IgE and Allergen-Specific IgE in a Real-World Study of <b>Pediatric</b> Patients With AD and Type 2 Comorbidities
Dermatology
Dupilumab Reduces Total IgE and Allergen-Specific IgE in a Real-World Study of Pediatric Patients With AD and Type 2 Comorbidities
expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares discusses evidence demonstrating that dupilumab reduces both total and allergen-specific IgE in pediatric patients with atopic dermatitis and comorbid allergic diseases, underscoring the role of IL-4/IL-13 blockade in modulating B-cell activity.

View more
ESPGHAN 2025
On Demand
Unlocking Better Outcomes: Strategies for Early Diagnosis and Effective Management in Pediatric EoE Patients

Pediatric gastroenterology experts Dr Carolina Gutiérrez Junquera and Dr Christos Tzivinikos where they discuss the importance of early identification and management of pediatric EoE to improve long-term outcomes. They highlight clinical data and discuss their practical experiences with pediatric EoE, including their perspectives on co-occurring type 2 inflammatory diseases, the chronic nature of EoE, and the future of EoE research and therapeutic development.

ESPGHAN 2026
On Demand
Pediatric EoE: An Interactive Learning Symposium

Join leading experts in pediatric eosinophilic esophagitis (EoE), Professors Salvatore Oliva, MD, PhD, and André Hörning, MD, as they explore the multifaceted journey of pediatric patients with EoE through a hypothetical patient case, navigating real-world challenges in managing EoE.

ESPGHAN 2025
Congress
16
May
2025
Congress
ADVENT at ESPGHAN 2025 | Unlocking Better Outcomes: Strategies for Early Diagnosis and Effective Management in Pediatric EoE Patients

In support of World Eosinophilic Esophagitis Day, this ADVENT symposium features pediatric gastroenterology experts Dr Carolina Gutiérrez Junquera and Dr Christos Tzivinikos where they discuss the importance of early identification and management of pediatric EoE to improve long-term outcomes. They highlight clinical data and discuss their practical experiences with pediatric EoE, including their perspectives on co-occurring type 2 inflammatory diseases, the chronic nature of EoE, and the future of EoE research and therapeutic development.

ESPGHAN 2026
Congress
26
June
2026
Congress
ADVENT at ESPGHAN 2026 | Pediatric EoE: An Interactive Learning Symposium

Join leading experts in pediatric eosinophilic esophagitis (EoE), Professors Salvatore Oliva, MD, PhD, and André Hörning, MD, as they explore the multifaceted journey of pediatric patients with EoE through a hypothetical patient case, navigating real-world challenges in managing EoE.

Why Is It Important to Assess Lung Function in <b>Pediatric</b> Asthma?
Pulmonology
Why Is It Important to Assess Lung Function in Pediatric Asthma?
interactivity

Learn about FEV1pp and the downstream effects of lung function decline in children with severe asthma.

View more
ADVENT On Air | Breath, Blood, and Beyond: The Prognostic Power of Biomarkers in Asthma Across Ages
Pulmonology
ADVENT On Air | Breath, Blood, and Beyond: The Prognostic Power of Biomarkers in Asthma Across Ages
Podcast

Join pediatric respirologist Dr. Sharon Dell and adult respirologist Dr. Simon Couillard as they discuss the prognostic and diagnostic power of asthma biomarkers and their impact on optimizing patient management across all ages.

View more
Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden
Dermatology
Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden
expert video

In this clip from the April WCPD 2025 symposium, Dr Paula Luna discusses how moderate-to-severe AD may hinder growth in pediatric patients.

View more
Hindered Growth in Children Aged <12 Years with Moderate-to-Severe AD and Potential Improvement with Dupilumab Treatment
Dermatology
Hindered Growth in Children Aged <12 Years with Moderate-to-Severe AD and Potential Improvement with Dupilumab Treatment
expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Amy Paller discusses how moderate-to-severe AD may hinder growth in pediatric patients and highlights data showing treatment with dupilumab may increase vertical growth in children of lower stature.

View more
Can Therapy-Free Disease Control Be Achieved in Atopic Dermatitis?
Dermatology
Can Therapy-Free Disease Control Be Achieved in Atopic Dermatitis?
expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Thomas Bieber discusses emerging evidence that therapy-free disease control may be possible in atopic dermatitis, citing pediatric dupilumab data showing that a subset of patients-maintained remission after treatment discontinuation.

View more
ADVENT On-Air Podcast: Growth and Children With AD
Dermatology
ADVENT On-Air Podcast: Growth and Children With AD
Podcast

Drs. Amy Paller and Lisa Swanson discuss the risk of low bone mineral density and impaired growth reported in pediatric atopic dermatitis and observed improvements in growth with advanced therapy, especially among children of shorter stature at baseline.

View more
KOL Video Interview – Dr Amy Paller
Dermatology
KOL Video Interview – Dr Amy Paller
expert video

In this exclusive video interview, Dr Amy Paller discusses two topics: 1) The importance of CCL17 (TARC) as a biomarker in pediatric patients with AD, and 2) How IL-4 and IL-13 contribute to skin barrier dysfunction in AD.

View more